Raphas Co. Ltd - Asset Resilience Ratio

Latest as of June 2026: 5.58%

Raphas Co. Ltd (214260) has an Asset Resilience Ratio of 5.58% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 214260 net working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

₩3.79 Billion

≈ $2.57 Million USD Cash + Short-term Investments

Total Assets

₩67.97 Billion

≈ $46.06 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2017–2025)

This chart shows how Raphas Co. Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Raphas Co. Ltd total assets.

Liquid Assets Composition Over Time

This chart breaks down Raphas Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Raphas Co. Ltd debt and liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	₩0.00	0%
Short-term Investments	₩3.79 Billion	5.58%
Total Liquid Assets	₩3.79 Billion	5.58%

Asset Resilience Insights

Limited Liquidity: Raphas Co. Ltd maintains only 5.58% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Raphas Co. Ltd Industry Peers by Asset Resilience Ratio

Compare Raphas Co. Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	2.50%
Dianthus Therapeutics Inc. NASDAQ:DNTH	Biotechnology	63.98%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	62.24%
Damora Therapeutics, Inc. NASDAQ:DMRA	Biotechnology	0.00%
Wecome Pharmaceutical Co Ltd SHE:300878	Biotechnology	0.67%
Tectonic Therapeutic, Inc. NASDAQ:TECX	Biotechnology	86.66%
Relmada Therapeutics Inc NASDAQ:RLMD	Biotechnology	95.25%
MediWound Ltd F:M8W	Biotechnology	56.04%

Annual Asset Resilience Ratio for Raphas Co. Ltd (2017–2025)

The table below shows the annual Asset Resilience Ratio data for Raphas Co. Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	13.15%	₩9.88 Billion ≈ $6.69 Million	₩75.08 Billion ≈ $50.88 Million	+3.49pp
2024-12-31	9.66%	₩7.35 Billion ≈ $4.98 Million	₩76.09 Billion ≈ $51.57 Million	-12.02pp
2023-12-31	21.69%	₩21.78 Billion ≈ $14.76 Million	₩100.40 Billion ≈ $68.04 Million	-11.09pp
2022-12-31	32.78%	₩31.49 Billion ≈ $21.34 Million	₩96.06 Billion ≈ $65.10 Million	-13.44pp
2021-12-31	46.22%	₩45.22 Billion ≈ $30.65 Million	₩97.84 Billion ≈ $66.31 Million	+22.39pp
2020-12-31	23.83%	₩14.25 Billion ≈ $9.66 Million	₩59.83 Billion ≈ $40.54 Million	-2.48pp
2019-12-31	26.30%	₩16.54 Billion ≈ $11.21 Million	₩62.88 Billion ≈ $42.62 Million	+12.85pp
2018-12-31	13.45%	₩4.64 Billion ≈ $3.15 Million	₩34.51 Billion ≈ $23.39 Million	-15.59pp
2017-12-31	29.04%	₩10.11 Billion ≈ $6.85 Million	₩34.81 Billion ≈ $23.59 Million	--

pp = percentage points

About Raphas Co. Ltd

KQ:214260 Korea Biotechnology

Market Cap

$42.74 Million

₩63.06 Billion KRW

Market Cap Rank

#22567 Global

#1460 in Korea

Share Price

₩7500.00

Change (1 day)

-1.06%

52-Week Range

₩6720.00 - ₩15350.00

All Time High

₩75400.00